TürkiyeDiagnosis and screening
Genetic childhood dystonia in Türkiye: 26 genes found in 81 children, 7 with the DYT1 gene
In Türkiye, 81 children from 19 centers were studied.
Neuromuscular diseases
An inherited movement disorder. The muscles contract involuntarily, and an arm or leg twists. It usually begins in childhood and does not affect intelligence.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Neuromuscular diseases” group.
A change in a gene called TOR1A disrupts communication between the nerve cells that control movement. As a result, the muscles contract involuntarily; this is called dystonia. Symptoms usually begin in one arm or leg. In some people, they spread over time to the trunk and to the other arms and legs.
Symptoms usually begin in childhood or the teenage years. They differ greatly from person to person, even within the same family.
The diagnosis is suspected from a neurological examination. A genetic test shows the change in the TOR1A gene. There is usually no visible structural problem in the brain.
Treatment aims to ease the symptoms. A movement disorder specialist becomes involved early on. Medicine and deep brain stimulation, a surgery to place a brain pacemaker, are among the options. Physiotherapy and occupational therapy make daily tasks easier. Regular follow-up is important. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through dominant inheritance. For each child of a parent with the gene change, the chance of inheriting the gene is 1 in 2. But only about one third of those who inherit the gene develop the disease. Severity can differ within the same family. Genetic counselling explains the risks to the family.
Source: MedlinePlus Genetics: Early-onset isolated dystonia · GeneReviews: DYT-TOR1A
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
TürkiyeDiagnosis and screening
In Türkiye, 81 children from 19 centers were studied.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
InternationalResearch and clinical trials
The HIMALAYA study, published in The Lancet Neurology, examined an experimental drug in patients with ALS (amyotrophic lateral sclerosis).
TürkiyeResearch and clinical trials
A multicenter study in Istanbul compared patients with Guillain-Barré syndrome.
USANew treatments and approvals
The US Food and Drug Administration (FDA) approved levacetylleucine for balance and walking problems in ataxia-telangiectasia (A-T).
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:256
No separate ICD-11 code; WHO classifies this disease under: 8A02.0Y
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.